Investor Presentaiton

Strategic highlights from Strive25 - Sustainable growth leadership • Growth US Chronic Care Strong performance in the US Ostomy Care business, where Coloplast continues to advance its competitive position Premier Inc. has renewed Coloplast's group purchasing agreement. The contract, which is multi-source, took effect on April 1, 2023, and is effective for three years China reopening • Coloplast is closely monitoring the market development in China and views the reopening as encouraging for the business on a mid- to long-term horizon • China remains a key strategic market for Coloplast and an important contributor to Coloplast's organic growth ambition in the Strive25 period Strive 25 SUSTAINABLE GROWTH LEADERSHIP Innovation Chronic Care - Clinical Performance Programme • . • Luja™, the new male intermittent catheter with a Micro-hole Zone Technology, has been launched in four markets, with positive initial feedback. The launch is progressing well, and the product is expected to be available in key markets over the next 9 months The results of the first pivotal clinical study have been published, showing a significant improvement in bladder emptying with Luja, compared to a competitor catheter* Heylo™, the new digital leakage platform, is in pilot launch in Germany and the UK and has been well-received by users. The clinical studies are on track and the product is expected to launch in 2023 Sustainability Improving products and packaging • Production waste recycling was 74% in H1 2022/23, up 10%-p from H1 2021/22. The solid progress reflects a continued scale up of the recycling partnership in Hungary Reducing emissions • Scope 1 and 2 emissions were reduced by 15% in H1 2022/23 vs. the base year 2018/19, positively impacted by the installation of electric heat pumps and electric equipment at production sites in Hungary and China in an effort to phase out natural gas Responsible operations - employee engagement Employee engagement score of 8.1, ahead of the healthcare industry benchmark of 7.6 Operational efficiency Global Operations Plan (GOP) 5 - Automation programme • Due to delays from longer component lead times, the timeline of the GOP5 automation programme is now extended into Q1 2023/24, from previously end of FY 2022/23 The ambition to release around 1,000 FTEs is unchanged Global Business Support and IT landscape • • Positive scale effect driven by further utilization of Business Centre and IT infrastructure. The integration of Atos Medical IT and finance infrastructure is progressing well - IT infrastructure integration will be finalized in May Coloplast remains on track to deliver estimated run-rate operational synergies of up to DKK 100 million, with full impact from FY 2023/24 4 Luja is a medical device for which CE-mark has been affixed. Product availability is subject to regulatory process of individual countries and is not guaranteed. *Study shows significant improvement in bladder emptying with Coloplast Luja™ compared to competitor catheter Coloplast

View entire presentation